Biomarkers for myelin oligodendrocyte glycoprotein-associated disease: recent advances and future
Qingying Zheng1,2, Muzi Wen1,2, Xinyi Zheng1,2
1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Abstract:
MOGAD is a rare autoimmune encephalomyelitis that shares similar clinical manifestations with other central nervous system demyelinating diseases. However, they must be distinguished due to their distinct pathogenesis and treatment methods. Currently, the clinical diagnosis of MOGAD primarily relies on patients' clinical manifestations and imaging features, with biomarker application being relatively limited. Meanwhile, research on MOGAD biomarkers has advanced rapidly, with findings mainly focusing on imaging features, antibody titers, nerve cell markers, cytokines, and inflammatory cell ratios. These biomarkers can distinguish among various autoimmune with similar clinical manifestations and exhibit certain specificity. If these biomarker findings are applied to the clinical diagnosis of MOGAD, they could enhance diagnostic accuracy and support earlier and more accurate diagnosis, while providing a scientific basis for evaluating disease progression and prognosis. We discuss the biomarkers and emerging biomarkers of MOGAD, emphasizing the specific changes and aspects that may be applicable to clinical diagnosis and treatment.
Insights
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) diagnosis can be improved using novel biomarkers. These biomarkers aid in distinguishing MOGAD from similar conditions, enhancing diagnostic accuracy and patient prognosis.
Area of Science:
- Neuroimmunology
- Autoimmune Diseases
- Central Nervous System Disorders
Background:
- Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune disorder.
- MOGAD presents with clinical symptoms similar to other central nervous system demyelinating diseases, necessitating accurate differentiation.
- Current MOGAD diagnosis relies heavily on clinical and imaging findings, with limited biomarker integration.
Purpose of the Study:
- To review current and emerging biomarkers for MOGAD.
- To highlight biomarkers that can improve diagnostic accuracy and differentiate MOGAD from mimic conditions.
- To discuss the potential clinical application of biomarkers for MOGAD diagnosis, progression, and prognosis.
Main Methods:
- Literature review of MOGAD biomarkers.
- Analysis of research findings on imaging features, antibody titers, nerve cell markers, cytokines, and inflammatory cell ratios.
- Discussion of biomarker specificity and potential for clinical application.
Main Results:
- Biomarker research in MOGAD is rapidly advancing.
- Identified biomarkers include imaging features, antibody titers, nerve cell markers, cytokines, and inflammatory cell ratios.
- These biomarkers show specificity in distinguishing MOGAD from other autoimmune diseases.
Conclusions:
- Biomarkers hold significant potential to enhance MOGAD diagnostic accuracy.
- Application of biomarkers can support earlier diagnosis and provide a basis for prognosis assessment.
- Further integration of biomarkers is crucial for advancing MOGAD clinical management.
